Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXOS110 in Acute Ischaemic Stroke (BEST)
NCT06322394Phase 2Recruiting
- Sponsor
- Biocells
- Start
- Feb 2024
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human prourokinase in ischemic stroke, sponsored by Biocells. Started Feb 2024; status: recruiting.
02
Drugs
recombinant human prourokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06322394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06322394.